3a,7a-dihydro-1H-indazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 3a,7a-dihydro-1H-indazole
• 英文别名: 3a,7a-Dihydroindazole
• 化学式: C₇H₈N₂
• 分子量: 120.154
• InChiKey: ATBLBFRIIROOHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-碘联苯 、 3a,7a-dihydro-1H-indazole 在 bis(tetrapropylammonium) tetraiododicuprate(I) 、 trans-1,2-cyclohexanediamine methanesulfonic acid 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以89%的产率得到1-([1,1'-biphenyl]-4-yl)-1H-indazole
  参考文献：
  名称：

  A Soluble Copper(I) Source and Stable Salts of Volatile Ligands for Copper-Catalyzed C–X Couplings

  摘要：

  A stable adduct of Cul with Bu4NI, soluble in organic solvents, has been identified as an effective catalyst for copper-catalyzed C-N and C-O couplings. In addition, stable nonhygroscopic salts of some high performance ligands (diamine MsOH salts/CuX and copper(II) diketonates) were shown to be of similar and sometimes greater reactivity compared to the literature reagents for these couplings. Furthermore, these more robust conditions result in more reproducible results.

  DOI：

  10.1021/jo300905w

文献信息

• Cationic diazo compounds, compositions comprising them as direct dye, process for dyeing keratin fibers and device therefor
  申请人：Greaves Andrew

  公开号：US20060005327A1

  公开（公告）日：2006-01-12

  The present disclosure relates to cationic diazo compounds chosen from those of formula (I) and the acid addition salts thereof: Dye1-LK-Dye2 (I); and to dye compositions comprising the the compounds as direct dye, and also to a process for dyeing keratin fibers using this composition and a multi-compartment device.

  本公开涉及选择自式(I)的阳离子重氮化合物及其酸盐：Dye1-LK-Dye2（I）；以及包含这些化合物作为直接染料的染料组合物，还涉及使用该组合物和多室装置染色角蛋白纤维的方法。
• [EN] GDF-8 INHIBITORS<br/>[FR] INHIBITEURS DU GDF 8
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2016133838A1

  公开（公告）日：2016-08-25

  Disclosed are 2,2'-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, Z and n are as described herein. In certain embodiments, a compound disclosed herein inhibits GDF8, and can be used to treat disease by blocking GDF8 signaling.

  本公开涉及2,2'-联吡啶化合物，以及其药物组合物和使用方法。 其中一种实施例是具有所述结构和药用可接受盐、前药和N-氧化物（以及其溶剂和水合物）的化合物，其中R1、Z和n如本文所述。 在某些实施例中，本文所披露的化合物抑制GDF8，并可用于通过阻断GDF8信号来治疗疾病。
• SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
  申请人：Global Blood Therapeutics, Inc.

  公开号：US20130190316A1

  公开（公告）日：2013-07-25

  Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

  提供了代替杂环醛和其衍生物，作为血红蛋白的异构调节剂，以及其制备的方法和中间体，包括该调节剂的药物组合物，以及在治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病中使用它们的方法。
• N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20150152109A1

  公开（公告）日：2015-06-04

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了一种公式(I)的化合物或其药学上可接受的盐；其中G是R1，R2和R3如此处所述；以及其药物组合物；以及在治疗动物中通过抑制乙酰辅酶A羧化酶酶的作用调节的疾病，病况或障碍中的使用。
• SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20140323730A1

  公开（公告）日：2014-10-30

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  该发明提供了公式（I）的化合物或其药学上可接受的盐；其中G是R1，R2和R3如此处所述；其药物组合物；以及在治疗动物中通过抑制乙酰辅酶A羧化酶酶的作用调节的疾病、病状或障碍中使用该化合物的方法。